What Is Retatrutide? The Triple Agonist (Reta) Explained
Research & educational use only. This content is not medical advice. Consult a qualified healthcare professional before using any peptide compound.
Retatrutide (development code LY3437943) is an investigational "triple agonist" — a single molecule that activates three metabolic receptors at once: GIP, GLP-1, and glucagon. It is the most closely watched metabolic peptide of 2026 because its trial weight-loss numbers have run higher than the approved GLP-1 drugs. It is not FDA approved and not available as a finished prescription product. This guide explains what retatrutide is, how it differs from tirzepatide and semaglutide, and what the evidence does and does not show. It is for research and educational purposes only, is not medical advice, and PeptidesHub does not sell peptides.
What is retatrutide?
Retatrutide is a single peptide designed to activate three receptors involved in metabolism and appetite: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. Because it hits three targets, it is often called a "triple agonist" or "GGG agonist." It is being developed by Eli Lilly and is still investigational — meaning it is in clinical testing, not on pharmacy shelves.
How does retatrutide differ from tirzepatide and semaglutide?
The difference is the number of receptors each one engages. Semaglutide (Ozempic, Wegovy) is a single GLP-1 agonist. Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 agonist. Retatrutide adds glucagon-receptor activity on top, making it a triple agonist — the theory being that glucagon activity may further increase energy expenditure. For structured side-by-sides, see tirzepatide vs retatrutide and semaglutide vs retatrutide.
What does the evidence show for retatrutide?
The headline data comes from a phase 2 randomized controlled trial published in the New England Journal of Medicine in 2023, which reported large, dose-dependent weight reductions at 48 weeks — numbers that exceeded what single and dual agonists showed in their own trials. Phase 3 trials (the TRIUMPH program) are ongoing in 2026. Important caveat: phase 2 results are promising but not final, cross-trial comparisons are not head-to-head, and longer-term safety in a broad population is still being established. See the retatrutide profile for the cited studies and evidence tier.
Is retatrutide FDA approved or available?
No. As of 2026 retatrutide is investigational, in phase 3 development, and is not FDA approved or sold as a finished prescription product. Any "retatrutide" offered for sale online is unapproved research-chemical material, not a regulated medicine — which means its identity, purity, and dosing accuracy are not guaranteed by anyone.
Retatrutide vs CagriSema: what’s the difference?
Both are next-generation metabolic candidates, but they work differently. Retatrutide is one molecule hitting three receptors. CagriSema is a combination of two molecules — semaglutide (a GLP-1 agonist) plus cagrilintide (a long-acting amylin analog). They represent two different strategies — a single triple-acting peptide versus a two-drug amylin-plus-GLP-1 combination — for pushing weight loss beyond what current GLP-1 drugs achieve.
What are the risks of sourcing retatrutide as a research chemical?
Because no approved retatrutide product exists, every gray-market vial is unregulated material of unknown quality. The risks are concrete: wrong identity, low purity, contamination, and inaccurate labeled amounts. If you are researching sources at all, treat third-party lab testing as mandatory — demand a batch-specific certificate of analysis from a named lab, check the ranked sellers directory and the warnings feed, and read how to vet a source. None of this is a recommendation to obtain or use retatrutide.